Today: 30 June 2026
Browse Category

NYSE:NVO 3 July 2025 - 15 October 2025

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

On Oct. 15, Novo Nordisk and Omeros announced a landmark deal licensing zaltenibart, Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseasesinvestor.omeros.com. Under the agreement, Novo pays $340M upfront and can pay up to $2.1 billion in total milestones and royalties for exclusive global rightsinvestor.omeros.comreuters.com. Reuters reports that Omeros stock “more than doubled to $9.90” in early trading after the newsreuters.com, and by market close had settled near $10.10investing.com. TechStock² notes Omeros shares surged roughly 65% on the announcementts2.tech. The deal is structured as an asset purchase and license – not an outright acquisition – and is expected to close in Q4 2025, after which Novo will launch a global Phase 3 trial in PNH and possibly other complement disordersts2.techreuters.com. Novonordisk’s CSO Martin Lange praised zaltenibart’s “novel mode of action” and potential advantages over existing complement therapiesinvestor.omeros.com. Omeros CEO Gregory Demopulos welcomed the partnership, saying he was “pleased to enter into this agreement with Novo Nordisk” and expects Novo’s global reach to “unlock the potential” of zaltenibartinvestor.omeros.com. According to ts2.tech, Omeros executives believe the deal “validates their research and funds further trials”ts2.tech. In effect, the transaction injects cash into Omeros and confirms interest in its drug pipeline.
15 October 2025
···
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart for all indications. Omeros will receive $340 million up front and near-term milestones, plus up to $2.1 billion total with development and sales milestones and tiered royalties Novonordisk. Reuters reported Novo would pay “up to $2.1 billion” for the experimental drug Reuters. The deal is structured as a licensing asset purchase, not a full acquisition, and is expected to close in Q4 2025 Marketscreener Novonordisk. Novo’s Chief Scientific Officer Martin Holst Lange described zaltenibart as having a “novel mode of action” with potential advantages over existing treatments Marketscreener. Omeros CEO Gregory Demopulos said he expects Novo’s global reach to “unlock the potential” of zaltenibart Marketscreener. The press release notes that Omeros keeps certain unrelated MASP-3 assets and will now concentrate on getting its lead MASP-2 antibody, narsoplimab, approved Marketscreener.
15 October 2025
···
Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Sources: Akero Therapeutics investor materials; Novo Nordisk press statements; Reuters, TS2.tech and FierceBiotechnews reportsts2.techts2.techfiercebiotech.com; MarketBeat and DirectorsTalk analyst surveysmarketbeat.comdirectorstalkinterviews.com; Economic Times deal summaryeconomictimes.indiatimes.comeconomictimes.indiatimes.com; Business Wire legal alertbusinesswire.combusinesswire.com; and TradingView market datamarketbeat.comtradingview.com.
9 October 2025
···
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Forecast: Experts believe that within the next 2–3 years, we’ll know if Novo’s gamble pays off. Phase 3 readouts for efruxifermin are anticipated in 2026, and Novo hopes to launch the drug by late this decade if approvedreuters.com. By then, the landscape may include other new NASH therapies, but Novo’s combination strategy could set it apart. Wolfe Research analyst Andy Chen recently said the field has reached a “meaningful tipping point” as the first therapies emerge, predicting the leading NASH drug could see $5 billion+ in annual sales under broad useinvesting.com. Novo’s own management clearly shares that optimism – they characterize EFX as a potential “first- and best-in-class” treatment for mid-to-late-stage fatty liver diseasebiospace.com. In the near term, investors seem cautiously optimistic: Novo’s stock has soared in 2025 thanks to obesity drug success, and adding Akero is seen as a bold but logical extension of that success into fatty liver disease. “This acquisition embodies Novo Nordisk’s relentless ambition to move faster, go further,” CEO Doustdar proclaimedbiospace.com. If efruxifermin fulfills its promise, Novo could not only help millions of patients with a previously untreatable condition, but also secure a new multi-billion dollar franchise – solidifying its position as a powerhouse in
9 October 2025
··
Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

German DAX index graph at the Frankfurt Stock Exchange, reflecting volatile mid-week trading reuters.com. European equities seesawed over the two days, buffeted by transatlantic trade tensions and shifting rate expectations. On Thursday Sept. 25, the STOXX Europe 600 index dropped 0.7%, touching levels not seen in three weeks reuters.com. Almost every major bourse closed in the red reuters.com as traders digested a slew of worrying signals: fresh U.S. trade investigations into high-tech imports, surprisingly robust U.S. economic data, and guarded comments from central bankers. By Friday Sept. 26, however, markets regained footing – the STOXX 600 ticked up roughly +0.3% by midday reuters.com and was on track to finish the eventful week slightly higher brecorder.com. The late-week relief came as investors pivoted to bargain-hunting in financial and industrial shares and awaited key U.S. inflation data for clues on interest rates reuters.com.
26 September 2025
········
Weekend Science Bonanza: Breakthroughs From Space to Superbugs

Weekend Science Bonanza: Breakthroughs From Space to Superbugs

Humanity’s search for cosmic neighbors hit a celebratory peak. NASA announced it has confirmed over 6,000 exoplanets – planets orbiting other stars – just three decades after finding the very first such world entechonline.com. This tally reflects an explosion of discoveries by telescopes like Kepler and TESS. “Each of the different types of planets we discover gives us information about… how common planets like Earth might be,” explained Dr. Dawn Gelino, who leads NASA’s exoplanet program, noting that every discovery helps us inch closer to answering the ultimate question of whether we’re alone sciencealert.com. The 6,000-planet milestone isn’t just a number – it highlights the diversity of alien worlds, from hot Jupiters to likely ocean planets, and guides scientists on where to hunt for habitable “Goldilocks” planets next sciencealert.com. Another cosmic first came from violent black hole mergers. For the first time, astronomers managed to measure the full recoil of a newly merged black hole – essentially catching nature’s most extreme cannonball in the act. Gravitational wave detectors had observed a 2019 black hole collision, and now a team led from Galicia, Spain analyzed the signal’s subtleties to reconstruct the merged black hole’s 3D motion phys.org phys.org. The result: the
21 September 2025
···
Ozempic for Alzheimer’s? How GLP-1 Weight-Loss Drugs Could Fight Neurodegenerative Diseases

Ozempic for Alzheimer’s? How GLP-1 Weight-Loss Drugs Could Fight Neurodegenerative Diseases

GLP-1 receptor agonists like semaglutide are typically given via a weekly injection pen. Originally developed for diabetes and obesity, these drugs are now being studied for their effects on the brain. Just a few years ago, GLP-1 receptor agonists were known mainly as diabetes and weight-loss medications. GLP-1 is a natural hormone that helps regulate blood sugar and appetite. Drugs like Ozempic and Victoza mimic this hormone, improving insulin release and promoting a feeling of fullness brightfocus.org. Their success in treating type 2 diabetes and inducing dramatic weight loss is well known – Ozempic and its sister drug Wegovy have become household names. Now, in 2025, scientists are uncovering surprising links between metabolic health and brain health, sparking trials of GLP-1 drugs for conditions like Alzheimer’s, Parkinson’s, and ALS.
10 September 2025
·
Glowing Planets, Monster Blooms & a ‘Next Ozempic’ – Science Highlights (Sept 1–2, 2025)

Glowing Planets, Monster Blooms & a ‘Next Ozempic’ – Science Highlights (Sept 1–2, 2025)

Baby Planet Still Glowing: In a landmark observation, astronomers directly imaged an infant planet still hot from its birth. The gas giant WISPIT 2b, roughly five Jupiters in mass and only ~5 million years old, was discovered orbiting within a multi-ring dust disk around a young star scitechdaily.com. Using the European Southern Observatory’s Very Large Telescope in Chile, the team captured WISPIT 2b shining in infrared – essentially catching it in the act of formation scitechdaily.com. It’s the first unambiguous photo of a planet in a multi-ring protoplanetary disk, offering a rare glimpse at early planet evolution scitechdaily.com. “Capturing an image of these forming planets has proven extremely challenging… it gives us a real chance to understand why… exoplanet systems out there look so diverse,” said Dr. Christian Ginski of University of Galway scitechdaily.com. Scientists are excited to study how WISPIT 2b interacts with its natal disk, which spans about 380 AU and features striking concentric rings potentially sculpted by the planet scitechdaily.com. Life’s Ingredients on Titan: Saturn’s haze-shrouded moon Titan might be brewing primitive cells in its alien lakes. NASA scientists announced that in Titan’s frigid methane–ethane lakes, simple organic molecules could spontaneously assemble into vesicles – tiny bubble-like
2 September 2025
·
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Targeted Fall Boosters, But Access Tightened: U.S. health authorities approved new monovalent COVID-19 vaccines updated for the 2025–26 season reuters.com. Unlike prior booster rollouts, the FDA restricted under-65 eligibility to those with risk factors, aligning with guidance from HHS Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic reuters.com. The change marks a sharp departure from broad eligibility in previous years. Officials and experts voiced concern that narrowing access could sow confusion over insurance coverage and leave many younger adults unprotected reuters.com reuters.com. Notably, the FDA also rescinded emergency authorization for Pfizer’s vaccine in children under 5, effectively pausing toddler immunizations reuters.com. Medical societies pushed back – the Infectious Diseases Society of America announced it is working with other groups on independent COVID vaccine guidelines, expected in September reuters.com. The American Academy of Pediatrics even went against federal policy, recommending that all young children get vaccinated for COVID-19 reuters.com. “Making America Healthy Again” or Undermining Science?: The narrower vaccine rollout comes amid turmoil at the CDC. CDC Director Dr. Susan Monarez was fired on Aug. 27, just weeks into the job, after clashing with HHS Secretary Robert F. Kennedy Jr. over his sweeping vaccine policy changes reuters.com reuters.com. Kennedy –
28 August 2025
····
Breakthrough Cures, Billion-Dollar Bets & Health Shockers – Global Biotech & Health News Roundup (Aug 23–24, 2025)

Breakthrough Cures, Billion-Dollar Bets & Health Shockers – Global Biotech & Health News Roundup (Aug 23–24, 2025)

Sources: FDA and company announcements via Reuters reuters.com reuters.com reuters.com reuters.com; FiercePharma and Reuters on industry moves reuters.com reuters.com; Pharmaceutical Executive on XtalPi deal prnewswire.com pharmexec.com; Reuters Health Rounds and JAMA Oncology for GLP-1 study reuters.com reuters.com; Reuters on injection coating and microbeads reuters.com reuters.com; Reuters on AAP vs HHS vaccine policy reuters.com reuters.com; Reuters on WHO budget and reorganization reuters.com reuters.com; ABC7 and KFF Health News on Legionnaires’ outbreak and legal action abc7ny.com abc7ny.com.
24 August 2025
···
Tariff Tsunami, Tech Tumble & Peace Talk Buzz – Global Business Roundup (Aug 19–20, 2025)

Tariff Tsunami, Tech Tumble & Peace Talk Buzz – Global Business Roundup (Aug 19–20, 2025)

Tech Selloff and Fed Jitters: U.S. stocks swung lower on August 19 as a tech-led slide dragged the Nasdaq down about 1.5%, even as the Dow Jones Industrial Average briefly touched a record high reuters.com reuters.com. High-flying AI names like Nvidia plunged, weighing on growth stocks, amid investor anxiety over the Federal Reserve’s upcoming Jackson Hole symposium reuters.com reuters.com. “There’s an anxiety about Powell’s comments at Jackson Hole… higher interest rates have a big impact on growth stocks,” noted Ross Mayfield of Baird, reflecting fears the Fed may stay hawkish despite market bets on rate cuts reuters.com reuters.com. Futures markets were pricing in at least two quarter-point Fed rate reductions by year-end reuters.com reuters.com, even as Fed officials grapple with inflation that’s still above target. Notably, U.S. 10-year Treasury yields eased to around 4.31%, after recently hitting multi-year highs reuters.com. The U.S. dollar strengthened for a third straight session ahead of Fed Chair Jerome Powell’s August 22 speech, pushing the dollar index up to a 1½-week high reuters.com reuters.com. Peace Talk Hopes Lift Europe: In Europe, equities rallied – the STOXX 600 index rose 0.7% on Aug 19 – buoyed by renewed hopes for a Ukraine peace deal reuters.com reuters.com.
20 August 2025
········
Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Sources: Key information and quotes in this report are sourced from recent Reuters news dispatches, official press releases, and expert commentary in credible outlets. For full details and further reading, please see the linked sources reuters.com reuters.com reuters.com reuters.com abcnews.go.com abcnews.go.com reuters.com reuters.com sciencedaily.com sciencedaily.com fiercehealthcare.com techstartups.com, among others. Each link corresponds to the original announcement or publication reporting the development in question. This roundup captures the major biotech, pharmaceutical, medical, and health news from August 17–18, 2025, highlighting the continuing innovations and challenges in the health sciences world. Let’s stay tuned as these stories evolve.
18 August 2025
·····
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

For the period August 15–16, 2025, the biotech, pharma, medical, and health sectors saw a flurry of significant developments worldwide. Here is a comprehensive roundup of the top stories, categorized by theme and featuring expert insights and source links: Novo Nordisk’s blockbuster weight-loss drug Wegovy received accelerated approval from the U.S. FDA to treat metabolic dysfunction-associated steatohepatitis, a serious fatty liver disease reuters.com. This makes Wegovy the first GLP-1 class therapy cleared for MASH, an ailment affecting roughly 5% of U.S. adults reuters.com. The decision was based on part 1 of an ongoing trial showing Wegovy improved liver health and scarring in more patients than placebo reuters.com. “There really [have] not been good treatments in this space… we really need better medications that… prevent the progression of the disease,” said Jason Brett, Novo Nordisk’s U.S. medical chief reuters.com. Novo is pursuing approvals in Europe and Japan based on these interim results reuters.com, potentially strengthening its lead in metabolic diseases. Rival Eli Lilly’s tirzepatide has also shown promise in MASH in mid-stage trials reuters.com, underscoring the high-stakes race in this therapeutic area.
16 August 2025
··········
All the Breakthroughs You Missed: The Biggest Science Stories from August 10–11, 2025

All the Breakthroughs You Missed: The Biggest Science Stories from August 10–11, 2025

Sources: The above summaries are based on reports and press releases from reputable outlets and journals, including The Guardian theguardian.com theguardian.com, Science sciencedaily.com sciencedaily.com, NASA space.com, ScienceDaily/RAS sciencedaily.com sciencedaily.com, Euronews euronews.com euronews.com, Reuters reuters.com reuters.com, Nature sciencedaily.com sciencedaily.com, and university press releases sciencedaily.com sciencedaily.com. Each story’s details and quotes are drawn from the original research publications or official statements by experts involved.
11 August 2025
·
Global Business Pulse: Markets Juggle Tariffs, Rate Cuts & Mega-Deals (Aug 7–8, 2025)

Global Business Pulse: Markets Juggle Tariffs, Rate Cuts & Mega-Deals (Aug 7–8, 2025)

Equities: Global stocks seesawed amid trade and geopolitical crosswinds. On Aug 7, Wall Street’s Dow Jones and S&P 500 slipped as pharma giant Eli Lilly plunged 14% on disappointing weight-loss drug data reuters.com reuters.com. The Nasdaq Composite inched to a record high, up 0.3%, buoyed by tech gains reuters.com reuters.com. “The market rally is beginning to look a little tired… ignoring a lot of the tariff news,” observed Spartan Capital’s Peter Cardillo, as investors had bid up stocks on strong earnings despite looming U.S. import levies reuters.com. In Europe, the pan-European STOXX 600 hit a one-week peak and notched its biggest rise in over two weeks on Aug 7 reuters.com, fueled by bank stocks and hopes of a Ukraine ceasefire after news of a possible Trump-Putin peace meeting reuters.com reuters.com. By Aug 8, European shares were on track for their best week in 12 weeks, aided by a perceived dovish tilt at the Fed and easing war fears reuters.com. Asia saw an uneven rebound – Japan’s Nikkei surged 2% to a record on robust earnings and optimism that U.S. tariffs on Japanese goods would be fine-tuned reuters.com reuters.com. However, Hong Kong, Korea and Australia lagged, reflecting fragile sentiment after Wall
8 August 2025
········
10 Game-Changing Science Breakthroughs in July 2025 – From Space to Health

10 Game-Changing Science Breakthroughs in July 2025 – From Space to Health

July 2025 has been a blockbuster month for science, with breakthroughs spanning the cosmos to cutting-edge medicine. From unprecedented interstellar visitors and sun-skimming spacecraft to life-saving medical advances and climate revelations, researchers worldwide delivered headline-making results. Below we round up the most important and fascinating science news of the month, complete with expert insights from those on the front lines of discovery. Astronomers have spotted a new interstellar comet, just the third such alien object ever observed passing through our solar system Reuters Reuters. Named 3I/ATLAS, the icy visitor was first detected on July 1 by the ATLAS survey telescope in Chile. Its bizarre trajectory revealed it came from far beyond our solar system, following predecessors ʻOumuamua and Borisov Reuters. Co-discoverer Larry Denneau of the University of Hawaii notes “beyond that we do not know very much” yet about this comet, with global efforts underway to observe its composition and behavior Reuters. Early estimates suggest 3I/ATLAS could be much larger than Borisov – possibly 10 km across – and currently sports only a faint coma Reuters. As it approaches the sun in October, scientists eagerly anticipate the comet’s activity: “We don’t know what will happen, so that’s exciting” Denneau says
13 July 2025
····
Digital Health & Telemedicine Industry Update (June–July 2025)

Digital Health & Telemedicine Industry Update (June–July 2025)

The summer of 2025 brought a surge of activity in digital health and telemedicine. Major telehealth providers announced mergers and strategic shifts, new virtual care platforms launched, and governments advanced telehealth-friendly policies. Below is a comprehensive roundup of key developments, market trends, regulatory updates, and tech advancements shaping the digital health sector in June and July 2025. Despite some uncertainty, the overall industry sentiment is optimistic. As one industry report noted, 81% of digital health leaders entered 2025 with an optimistic outlook fiercehealthcare.com, having weathered funding dips and proved the resilience of virtual care models. Telehealth usage remains far above pre-pandemic levels, and both patients and providers have grown accustomed to its convenience. With significant investments, policy tailwinds, and technology breakthroughs all underway, digital health is poised to continue its rapid evolution through 2025 and beyond – delivering care that is more accessible, data-driven, and patient-centered than ever before.
3 July 2025
····
1 … 5 6 7

Stock Market Today

  • Talawar Therapeutics to List Nasdaq as It Raises $285M for Atopic Dermatitis Drug
    June 30, 2026, 8:18 AM EDT. Talawar Therapeutics will go public on Nasdaq as 'TLWR' after pulling in $225 million through a PIPE plus $60 million from SPAC JATT II Acquisition, raising $285 million in total. The New Jersey biotech is developing TALA-125, an IL-13/IL-18 bispecific antibody aimed at atopic dermatitis, and is going up against Sanofi and Regeneron's top-selling Dupixent. Talawar says this new approach could get past limits of current therapies by targeting two immune pathways. The company expects to start Phase IIb trials by early 2027, with data coming in late 2028. AD sales could hit $22.4 billion by 2033, even as the field still sees unmet need.
Go toTop